Evidence map›Paper›PMID 34842984›Full record

Trial reportGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2022

SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion.

Ingrid U Scott, Neal L Oden, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, SCORE2 Investigator Group

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. The Association between Retinal Thickness Fluctuations and Visual Outcomes under Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-Analysis.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2024
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Ingrid U ScottDepartments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.
Neal L OdenThe Emmes Company, LLC, 401 N. Washington Street, Suite 700, Rockville, MD, USA.
Paul C VanVeldhuisenThe Emmes Company, LLC, 401 N. Washington Street, Suite 700, Rockville, MD, USA. score2@emmes.com.
Michael S IpDoheny Eye Institute, University of California, Los Angeles, CA, USA.
Barbara A BlodiUniversity of Wisconsin Fundus Photograph Reading Center, Madison, WI, USA.
SCORE2 Investigator Group
Emmes (United States) · USPenn State Milton S. Hershey Medical Center · USUniversity of California, Los Angeles · USUniversity of Wisconsin Foundation · US

Funding

SCORE2 Comparative Trial (SCT)U10EY023533 · NEI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SCOTT, INGRID U · 2013 to 2018
$7.4M
SCORE2 Comparative Trial (SCT)U10EY023529 · NEI · THE EMMES COMPANY, LLC · PI VAN VELDHUISEN, PAUL C · 2013 to 2018
$6.8M
The SCORE2 Long-Term Follow-Up (SCORE2 LTF)UG1EY023533 · NEI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SCOTT, INGRID U · 2019 to 2021
$3.7M
SCORE2 Comparative Trial (SCT)U10EY023521 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI BLODI, BARBARA A · 2013 to 2018
$1.8M
NEI NIH HHS 1U10EY023521NEI NIH HHS 1U10EY023529NEI NIH HHS 1U10EY023533NEI NIH HHS U10 EY023521NEI NIH HHS U10 EY023529NEI NIH HHS U10 EY023533NEI NIH HHS UG1 EY023533
6 · The paper itself

Abstract

purposeTo evaluate macular thickness fluctuations and their association with visual acuity outcome in eyes with macular edema (ME) secondary to central (CRVO) or hemiretinal vein occlusion (HRVO) treated initially with intravitreal aflibercept or bevacizumab.

methodsPost hoc analysis of 362 patients with ME secondary to CRVO or HRVO initially randomized to six monthly intravitreal injections of aflibercept or bevacizumab. Three spectral domain optical coherence tomography (SD-OCT) central subfield thickness (CST) fluctuation measures were investigated over Months 1-12: standard deviation (SD), number of turning points (T) for each participant, and a measure denoted as Zigzag reflecting the magnitude of alternating ups and downs in a participant's CST. Main outcome measure is Month 12 visual acuity letter score (VALS).

resultsMore fluctuations occurred in eyes randomized to bevacizumab than aflibercept: SD (59.98 vs 32.12; p < 0.0001), T (4.03 vs 3.53; p = 0.02) and Zigzag (24.91 vs 11.60; p = 0.0003). Month 12 VALS is significantly lower for the 4th (highest) quartile of the CST fluctuation measure than for the 1st (lowest) quartile for both SD (mean difference in VALS of 7.87; 95% confidence interval: 3.03, 12.70) and Zigzag (mean difference in VALS of 5.11; 95% confidence interval: 0.29, 9.93). SD and Zigzag quartiles were no longer significantly different after Month 1 VALS was added to the regression analysis.

conclusionsGreater CST fluctuation as assessed by SD and Zigzag was negatively associated with Month 12 VALS. However, early post-treatment VALS is a stronger predictor of VALS outcomes than the CST fluctuation measures.

Indexed as

Macular EdemaRetinal Vein OcclusionAngiogenesis InhibitorsBevacizumabHumansIntravitreal InjectionsTomography, Optical CoherenceTreatment OutcomeValsartanVascular Endothelial Growth FactorsAngiogenesis InhibitorsBevacizumabValsartanVascular Endothelial Growth FactorsAnti-VEGF treatmentCentral retinal vein occlusionHemiretinal vein occlusionMacular edemaMacular thickness fluctuationVisual acuity

Identifiers

PMID34842984
PMCPMC10887424
OpenAlexW3216127258

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.